CSTL Profile
Castle Biosciences Inc (CSTL) is a commercial-stage dermatological cancer company. The company develops and commercializes diagnostic and prognostic tests that provide actionable information for the treatment of cancer patients. Castle Biosciences' proprietary technology platform enables the identification of unique molecular signatures for various cancers, which helps to enhance the diagnosis and management of patients.
The company's flagship product is the DecisionDx-Melanoma test, which is a gene expression profile test that helps to predict the risk of metastasis or recurrence for patients with invasive cutaneous melanoma. The company has also developed DecisionDx-UM, a similar test for uveal melanoma, and DecisionDx DiffDx-Melanoma, a test that helps distinguish melanoma from benign skin lesions.
Castle Biosciences is also developing additional diagnostic and prognostic tests for other types of cancer. The company has ongoing research programs in cholangiocarcinoma and glioma, among other indications.
Headquartered in Friendswood, Texas, Castle Biosciences was founded in 2008 and went public in 2019. The company is committed to improving cancer patient care by providing accurate diagnostic and prognostic tests to help guide treatment decisions.
|
